CPhI Worldwide, organised by UBM EMEA, formally launches a new partnership with international charity Global Angels, to help promote its efforts and encourage support from the pharmaceutical industry.
The goal is to harness CPhI’s global reach to actively deliver support and funds from inside the pharma industry to Global Angels – a charity that partners with innovative projects to deliver tangible, life saving results in developing countries.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7522851-cphi-agreement-global-angels/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
People in the UK, who currently have significantly poorer access to cancer medicines compared to those in Europei, could soon be gaining access to life saving cancer treatments which are currently not available on the NHS, with the launch of the Cancer Drugs Fund. The interim funding of £50 million for cancer drugs made available today is ahead of the introduction of a longer term Cancer Drugs Fund of £600 million from 2011-2014.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/wishingwall/46284/
The day when a surgeon can pull a new human vein “off the shelf” for use in life-saving vascular surgeries is now one step closer to reality. New research published in the current issue of the journal Science Translational Medicine demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/humacyte/48336/
